Opicapone
Ongentys (opicapone) is a small molecule pharmaceutical. Opicapone was first approved as Ongentys on 2016-06-24. It is used to treat parkinson disease in the USA. It has been approved in Europe to treat parkinson disease. The pharmaceutical is active against catechol O-methyltransferase. Ongentys's patents are valid until 2035-05-27 (FDA).
Trade Name | Ongentys |
---|---|
Common Name | Opicapone |
Indication | parkinson disease |
Drug Class | Catechol-O-methyltransferase (COMT) inhibitors |